SHANGHAI JUNSHI Aktie

 

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates....

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage. JS001sc is independently developed by Junshi Biosciences as a subcutaneous The post Junshi receives China's NMPA acceptance for toripalimab injection appeared first on Pharmaceutical Business review....

NDAs for Toripalimab Injection (Subcutaneous) Across 12 Indications accepted by the NMPA...

SHANGHAI and HONG KONG, Feb. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for......

Jointly evaluate the synergistic therapeutic potential of JS207 (PD-1/VEGF BsAb) and ATG-037 (oral small-molecule CD73 inhibitor)...

CNE100003F19 CNE100003FC4 CNE100003FF7 CNE100003FL5 CNE100003K53 CNE100003KK7 CNE100003PH2 CNE1000040M1 CNE100004JD2 CNE1000055Z1 CNE1000057K9 CNE100005RV4 CNE100006624 CNE1000069Z2 CNE100006JG0 CNE100006M66 CNE100006N08 CNE100006NF4 CNE100006NX7 CNE100006QK7 CNE100006S86 CNE100006T02 CNE100006V73 CNE100006Z61 CNE100006Z79 CNE1000070H8 CNE1000070L0 CNE1000076P8 CNE100007C18 CNE100007CV2 CNE100007DG1 CNE100007DW8 CNE100007F07 CNE100007F72 CNE100007F98 CY0103562118 DE000A0N3UD5 DE000A351SC5 DK0060817898 DK0061026119 DK0061078425 DK0061123312 DK0061407699 DK0061408580 DK0061411964 DK0061417144 DK0061536828 DK0061675006 DK0061805660 DK0063855085 HK0000120151 HK0000504214 HK0000527306 HK0000544194 HK0000709128 HK0000735800 HK0000827664 HK0000981941 HK0014000126 HK0345001611 HK0521001989 HK0560006634 HK0836012952 ID1000058407 ID1000074008 ID1000094204 ID1000097207 ID1000100209 ID1000110000 ID1000118300 ID1000125107 ID1000125909 ID1000165004...

BLA of Roconkibart (IL-17A) for the treatment of moderate to severe plaque psoriasis has been accepted by the NMPA...

The phase 3 study of toripalimab's subcutaneous injection (JS001sc) has met primary endpoints...

FDA has approved Junshi Biosciences' IND for a Phase 2/3 clinical study of JS207 (PD-1/VEGF), for the neoadjuvant treatment of NSCLC...

JS005 has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study...

Junshi Biosciences announced its 2025 interim financial results and provided corporate updates....

SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the supplemental new drug application (“sNDA”) for toripalimab (trade name: TUOYI®) in combination with disitamab vedotin, an antibody-drug conjugate (“ADC”) developed by RemeGen Co., Ltd. as the treatment of HER2-expressing (HER2 expression is defined as a HER2 immunohistochemistry test result of 1+, 2+, or 3+) locally advanced or metastatic urothelial carcinoma (“UC”), has been accepted by the National Medical Products Administration (“NMPA”). This is toripalimab's 13th application for marketing submitted in the Chinese mainland....

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Some countries and regions in Asia recently saw an increase in the number of COVID-19 cases. According to Nikkei Asia, hundreds of thousands of COVID-19 cases have been reported in countries including China and Singapore, killing at least 46 people in Thailand alone. An Zhijie, a researcher at the Chinese Center for Disease Cont......

COVID-19 has become way more active in both Mainland China and Hong Kong recently. According to data from the Chinese Center for Disease Control and Prevention, the COVID-19 positivity rate among outpatient and emergency flu-like cases in the Mainland increased from 7.5% to 16.2% during the period from end-March to May 4.Shares ......

BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing a next-generation therapeutic. BioDlink provided end-to-end......

Toripalimab was approved by the NMPA as the first-line treatment for unresectable or metastatic melanoma, the 12th indication in the Chinese mainland....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates....

Junshi Biosciences' toripalimab (LOQTORZI®) was approved as the first and only approved immuno-oncology treatment for NPC in Singapore....